Intellipharmaceutics International Stock Current Asset
Intellipharmaceutics International fundamentals help investors to digest information that contributes to Intellipharmaceutics' financial success or failures. It also enables traders to predict the movement of Intellipharmaceutics OTC Stock. The fundamental analysis module provides a way to measure Intellipharmaceutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Intellipharmaceutics otc stock.
Intellipharmaceutics |
Intellipharmaceutics International OTC Stock Current Asset Analysis
Intellipharmaceutics' Current Asset is all of the company's assets that can be used to pay off current liabilities within the current fiscal period or over the next 12 months. Current Asset includes cash or cash equivalents, accounts receivable, short-term investments, and the portion of prepaid liabilities which will be paid within the next 12 months. Because these assets are easily turned into cash, they are sometimes referred to as liquid assets.
Current Intellipharmaceutics Current Asset | 1.41 M |
Most of Intellipharmaceutics' fundamental indicators, such as Current Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Intellipharmaceutics International is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Current Asset is important to company's creditors and private equity firms as they will often be interested in how much that company has in current assets since these assets can be easily liquidated in case the company goes bankrupt. However, it is usually not enough to know if a company is in good shape just based on current asset alone; the amount of current liabilities should always be considered.
CompetitionIn accordance with the recently published financial statements, Intellipharmaceutics International has a Current Asset of 1.41 M. This is 99.93% lower than that of the Pharmaceuticals sector and 99.87% lower than that of the Health Care industry. The current asset for all United States stocks is 99.98% higher than that of the company.
Intellipharmaceutics Current Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Intellipharmaceutics' direct or indirect competition against its Current Asset to detect undervalued stocks with similar characteristics or determine the otc stocks which would be a good addition to a portfolio. Peer analysis of Intellipharmaceutics could also be used in its relative valuation, which is a method of valuing Intellipharmaceutics by comparing valuation metrics of similar companies.Intellipharmaceutics is currently under evaluation in current asset category among its peers.
Intellipharmaceutics Fundamentals
| Return On Asset | -0.98 | |||
| Operating Margin | (106.06) % | |||
| Current Valuation | 4.47 M | |||
| Shares Outstanding | 33.09 M | |||
| Shares Owned By Insiders | 1.70 % | |||
| Shares Owned By Institutions | 11.09 % | |||
| Number Of Shares Shorted | 714 K | |||
| Price To Earning | (0.50) X | |||
| Price To Sales | 66.19 X | |||
| Gross Profit | 1.4 M | |||
| EBITDA | (4.45 M) | |||
| Net Income | (5.15 M) | |||
| Cash And Equivalents | 79.65 K | |||
| Total Debt | 2.01 M | |||
| Debt To Equity | 165.20 % | |||
| Current Ratio | 0.05 X | |||
| Book Value Per Share | (0.31) X | |||
| Cash Flow From Operations | (2.46 M) | |||
| Short Ratio | 0.39 X | |||
| Earnings Per Share | (0.16) X | |||
| Target Price | 25.0 | |||
| Number Of Employees | 11 | |||
| Beta | 1.0 | |||
| Market Capitalization | 2.02 M | |||
| Total Asset | 2.1 M | |||
| Retained Earnings | (86.55 M) | |||
| Working Capital | (5.62 M) | |||
| Current Asset | 1.41 M | |||
| Current Liabilities | 7.02 M | |||
| Z Score | -65.8 | |||
| Net Asset | 2.1 M |
Currently Active Assets on Macroaxis
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. You can also try the Transaction History module to view history of all your transactions and understand their impact on performance.
Other Consideration for investing in Intellipharmaceutics OTC Stock
If you are still planning to invest in Intellipharmaceutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Intellipharmaceutics' history and understand the potential risks before investing.
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges |